Atacicept
Phase 3Protein / enzyme
EMD SeronoAtacicept is a protein / enzyme that works as a Tumor Necrosis Factor Ligand Superfamily Member 13b Inhibitor; Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor.[2] It is being investigated across 12 indications, with its most advanced program in Phase 3.[1]
Atacicept is one of 222 small molecule programs targeting Systemic Lupus Erythematosus. It is currently in Phase 3.
12
Indications
18
Total Trials
4
Active Trials
221
Competitors
Pipeline
Status by Indication[3][1]
Indication
Showing 10 of 12 indications
Competition
Competitive Landscape
1774 competitors in Lymphoma
#DrugCompanyPhaseTrials
1Atacicept
EMD SeronoPhase 3
Oncaspar
SServier
Preclinical
Velban
EEastern Cooperative Oncology Group
Preclinical
Zofran
NovartisPreclinical
Norvir
AbbViePreclinical
Tafasitamab
IncytePreclinical
Systemic Therapy
Bristol-Myers SquibbPreclinical
Elitek
AAzienda U.S.L. 1 di Massa e Carrara
Preclinical
PEG-Intron
Merck & Co.Preclinical
Rhg-CSF
CCSPC Baike (Shandong) Biopharmaceutical Co., Ltd.
Preclinical
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Timeline
Expected Milestones
Clinical
Trials by Indication[1]
Rheumatoid Arthritis3 trials
Lupus Nephritis3 trials
IgA Nephropathy2 trials
Systemic Lupus Erythematosus2 trials
6 more indications
Long-term Follow-up1 trial
pMN1 trial
IgA Nephropathy (IgAN)1 trial
Unspecified1 trial
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for Atacicept. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Mechanism of Action
- Tumor Necrosis Factor Ligand Superfamily Member 13b Inhibitor; Tumor Necrosis Factor Ligand Superfamily Member 13 Inhibitor[2]
- Modality
- Protein / enzyme[2]
- Highest Phase
- Phase 3[1]
- Company